MediPharm Labs is a global leader in high-quality, pure and trusted medical and adult-use cannabis products, supplying Canada and international markets where the regulatory jurisdictions permit. In addition to making its own MediPharm Labs family of medicinal and adult-use products, the company also manufactures white label products and conducts contract manufacturing for others. They formulate, complete sensory tests, process, package, label, and distribute cannabis extracts and advanced cannabinoid-based products, including popular products like the Wayfarer-branded vape cartridges.
“Since delivering the first shipment of our Cannabis 2.0 products late last year, demand for our finished products continues to increase,” says Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “New consumers and a growing list of private retailers across Canada are beginning to form opinions and make brand choices based on quality, potency, price, and availability of consistent supply. So far, we’re earning our place with tremendously positive feedback.”
In late December 2019, the company started shipping their Cannabis 2.0 products to Canada’s provincial retailers/distributors, and as of May, products are on sale in select provinces such as British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario. MediPharm Labs continues to maintain distribution agreements with all provinces/territories across Canada, so watch for future availability of their products across Canada.
Based in Barrie, Ontario, the company’s facility, which is built and certified to pharmaceutical standards is currently one of the most innovative and technically advanced in Canada with state-of-the-art technology, downstream purification methodologies, and five primary extraction lines to deliver pure, trusted, and precisely-doseable cannabis products for their customers. Most importantly, MediPharm Labs is committed to manufacturing products of the highest quality that provide trust through a predictable and consistent experience for patients and consumers. That’s why all of their product offerings begin with high quality dried cannabis, sourced from select licensed cultivators based on their quality standards, reputation, and reliability. All other inputs, such as hardware, are evaluated against appropriate quality standards. After processing, a representative sample from every batch of cannabis is tested externally by a qualified third-party laboratory. To ensure these pharma-quality standards, MediPharm Labs has invested in an expert, research-driven and quality-focused team with over 155 years of cumulative experience working in regulated industries such as pharmaceutical, food and beverage, nutraceuticals, medical devices, and cannabis.
The Wayfarer Brand
MediPharm Labs’ purified, trusted cannabinoid-based products include the Wayfarer line of vape cartridges, including many well-known cannabis cultivars.
- Northern Lights is a popular high-THC distillate with terpinolene, limonene, and beta-caryophyllene terpenes.
- Blue Dream is another popular high-THC distillate with alpha-pinene, myrcene, and beta-caryophyllene terpenes, as well as some floral notes.
- AC/DC (2:1 CBD: THC) is a popular phenotype of high CBD – low THC ratio with dominant myrcene, beta-caryophyllene, and limonene terpenes.
- Pink Kush (Coming Soon)
- GG4 (Coming Soon)
All of these inhalable products are designed to deliver a pure, clean taste, and are formulated with 95% distillate and 5% terpenes, and no carrier oil, highlighting the quality of MediPharm Labs’ cannabis extracts.
Innovation & Research
MediPharm Labs is among a select number of cannabis companies that have obtained their Research Licence under the Cannabis Act and Cannabis Regulations. The licence allows its Research & Development Team to perfect cannabis extracts and concentrates, distillates, oil, edibles, topicals, and terpenes through controlled ‘human administration trials’. With this licence, MediPharm Labs can use sensory experiments in relation to taste, aroma, or touch (for topicals) thus expanding their understanding of the consumer response profile and ultimately of consumer preferences for the raw material, in-process material, and finished products. The results of such trials that evaluate the aroma, palatability and tactile properties helps the company ensure greater desirability of their products. Other innovations MediPharm Labs’ R&D team is researching include water-solubility and isolating specific cannabinoids for future use in novel cannabis products.
Legalization of Cannabis 2.0 and the rollout of new retailers across Canada should mean an even greater product choice and accessibility for consumers as 2020 progresses. Due to its diversified manufacturing platform, MediPharm Labs can supply all product categories: cannabis extracts (bottled cannabis oil, vapes), cannabis topicals, and edible cannabis (beverages and food products), while adhering to pharma-quality at scale, and maintaining its reputation as a trusted global leader in cannabinoid-based products.